These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 24726140)

  • 41. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
    Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
    Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
    Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.
    Caram MV; Schuetze SM
    J Surg Oncol; 2011 Dec; 104(8):888-95. PubMed ID: 22069173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Src activity is increased in gastrointestinal stromal tumors--analysis of associations with clinical and other molecular tumor characteristics.
    Rotert JV; Leupold J; Hohenberger P; Nowak K; Allgayer H
    J Surg Oncol; 2014 May; 109(6):597-605. PubMed ID: 24391050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
    Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
    World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PCAT6 mediates cellular biological functions in gastrointestinal stromal tumor via upregulation of PRDX5 and activation of Wnt pathway.
    Bai F; Zhang N; Fang W; He X; Zheng Y; Gu D
    Mol Carcinog; 2020 Jun; 59(6):661-669. PubMed ID: 32339330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of gastrointestinal stromal tumors: looking beyond the knife. An update on the role of adjuvant and neoadjuvant imatinib therapy.
    Pandey R; Kochar R
    J Gastrointest Cancer; 2012 Dec; 43(4):547-52. PubMed ID: 22847491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Morphological characteristics and prognostic criteria for gastrointestinal stromal tumors].
    Tsyganova IV; Anurova OA; Mazurenko NN
    Arkh Patol; 2011; 73(6):37-42. PubMed ID: 22379899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Tarn C; Rink L; Merkel E; Flieder D; Pathak H; Koumbi D; Testa JR; Eisenberg B; von Mehren M; Godwin AK
    Proc Natl Acad Sci U S A; 2008 Jun; 105(24):8387-92. PubMed ID: 18550829
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
    Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors.
    Ogata K; Mochiki E; Ojima H; Haga N; Fukuchi M; Aihara R; Ando H; Uchida N; Toyomasu Y; Suzuki M; Kimura A; Kogure N; Yokobori T; Ohno T; Kuwano H
    J Surg Oncol; 2014 Dec; 110(8):942-6. PubMed ID: 25164620
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients.
    Yoon S; Ryu MH; Yoo C; Beck MY; Ryoo BY; Kang YK
    J Korean Med Sci; 2013 Aug; 28(8):1248-52. PubMed ID: 23960456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
    [No Abstract]   [Full Text] [Related]  

  • 55. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells.
    Park EH; Kim S; Jo JY; Kim SJ; Hwang Y; Kim JM; Song SY; Lee DK; Koh SS
    Carcinogenesis; 2013 Mar; 34(3):694-702. PubMed ID: 23222813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CT scan is not everything in the evaluation of a patient with gastrointestinal tumors (GIST) under imatinib therapy.
    Wang CM; Fu H; Zhao GF; Wang J; Shi YQ
    Pathol Oncol Res; 2012 Oct; 18(4):1095-7. PubMed ID: 21927980
    [No Abstract]   [Full Text] [Related]  

  • 58. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
    Floris G; Sciot R; Wozniak A; Van Looy T; Wellens J; Faa G; Normant E; Debiec-Rychter M; Schöffski P
    Clin Cancer Res; 2011 Sep; 17(17):5604-14. PubMed ID: 21737509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P; Bylina E; Klimczak A; Switaj T; Falkowski S; Kroc J; Lugowska I; Brzeskwiniewicz M; Melerowicz W; Osuch C; Mierzejewska E; Wasielewski K; Woźniak A; Grzesiakowska U; Nowecki ZI; Siedlecki JA; Limon J
    BMC Cancer; 2012 Mar; 12():107. PubMed ID: 22439647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.